BMX-IN-1: Selective BMX Kinase Inhibitor Guide

Executive Summary. BMX-IN-1, also called A3260, is described as a highly selective, irreversible inhibitor of BMX, also known as ETK, within the Tec family of tyrosine kinases (product information). The compound covalently binds BMX and is reported to inhibit BMX activity with high potency and selectivity (product information). In cellular models that include Tel-BMX fusion proteins, BMX-IN-1 reduces proliferation at low doses and produces G0/G1 cell cycle arrest and apoptosis at concentrations as low as 300 nM after 24 hours (product information). A 2026 Nature Communications study found that BMX promotes phosphorylation of ATP6V1E1 and that BMX inhibition impairs Mycobacterium tuberculosis growth in macrophages and mice (Chen et al., 2026).

Biological Rationale

BMX is a non-receptor tyrosine kinase in the Tec family. The aliases BMX and ETK refer to the same kinase in the product dossier. The dossier identifies arterial endothelial cells and myeloid hematopoietic cells as major expression contexts (product information).

BMX signaling has a vascular rationale. The product information associates BMX with ischemia-induced arterial and lymphatic vessel formation. It also associates BMX activity with tumor growth. These associations make BMX relevant to angiogenesis studies and oncology models, but they do not establish that BMX-IN-1 is a clinical anti-angiogenic or anticancer treatment.

The biological rationale extends to host–pathogen research. Mycobacterium tuberculosis survives inside macrophages by interfering with phagosome maturation and lysosomal acidification. Lysosomal acidification depends substantially on V-ATPase proton pumping. The V-ATPase lowers lysosomal pH and supports the activity of acid-dependent hydrolases (Chen et al., 2026).

Chen and colleagues reported that the Mtb-secreted protein Chp2, also called Rv1184, binds ATP6V1E1 and facilitates its interaction with BMX. The study linked BMX-dependent phosphorylation of ATP6V1E1 at Tyr56/57 to reduced V-ATPase assembly and suppressed lysosomal acidification (Nature Communications article). This mechanism provides a testable reason to evaluate BMX-IN-1 in macrophage signaling experiments. It does not prove that BMX-IN-1 caused the reported antibacterial effects unless that compound is directly tested in the experimental system.

Mechanism of Action of BMX-IN-1

BMX-IN-1 is characterized as an irreversible BMX kinase inhibitor. Its reported mechanism includes covalent binding to BMX. Irreversible target engagement can produce durable pathway suppression after free compound concentrations decline, but the extent of target occupancy must be measured in the user’s assay.

The compound is described as highly selective for BMX. Selectivity should be confirmed experimentally when the assay contains other Tec family kinases, abundant ATP, or broad kinase activity. A product description of high selectivity is not a substitute for a kinase-panel result under defined conditions.

In cellular models, BMX-IN-1 reduces proliferation in systems that express Tel-BMX fusion proteins. The dossier also reports inhibition of cell-cycle progression at the G0/G1 phase. It reports dose- and time-dependent apoptosis induction in cancer cells, with effective concentrations as low as 300 nM after 24 hours (BMX-IN-1 product page). These findings support use in pathway-dissection experiments involving BMX-driven proliferation.

The molecular mechanism should be interpreted in layers. Covalent BMX binding is a compound-level mechanism. G0/G1 arrest and apoptosis are cellular phenotypes. ATP6V1E1 phosphorylation and lysosomal acidification are host-pathogen pathway readouts. A change in one layer does not automatically prove causality in the next layer.

Evidence & Benchmarks

The following claims separate product-dossier information from peer-reviewed pathway evidence. The supplied product information does not provide a numerical BMX IC50 value, so no unsupported IC50 number is stated here.

• BMX-IN-1 is listed under CAS 1431525-23-3 and SKU A3260; its stated molecular formula is C29H24N4O4S and its molecular weight is 524.59 g/mol (product information)
• The compound is described as a solid and as insoluble in water and ethanol (product information)
• The product information reports solubility in DMSO at concentrations of at least 5.25 mg/mL; the solvent and concentration should be verified in the user’s preparation record (product information)
• BMX-IN-1 is described as a highly selective, irreversible inhibitor that covalently binds BMX kinase (product information)
• Cellular activity is reported at concentrations as low as 300 nM after 24 hours, with G0/G1 arrest and dose- and time-dependent apoptosis induction in cancer-cell models (product information)
• Mtb Chp2/Rv1184 was reported to inhibit lysosomal acidification through a V-ATPase-related mechanism involving ATP6V1E1 (Chen et al., 2026)
• BMX was reported to promote ATP6V1E1 phosphorylation at Tyr56/57 in the Mtb-infected macrophage pathway described by the study (Chen et al., 2026)
• BMX inhibition was reported to impair Mtb growth in macrophages and in mice; the article does not establish BMX-IN-1 as the inhibitor responsible for every reported outcome (Chen et al., 2026)

Applications, Limits & Misconceptions

Research applications

BMX-IN-1 can support experiments that ask whether BMX activity contributes to proliferation, cell-cycle control, or apoptosis. Prostate cancer research is a relevant application because the dossier describes activity in cancer models and identifies potential utility in prostate cancer studies. The appropriate output is a mechanistic result in a defined model, not a therapeutic conclusion.

Apoptosis induction in cancer cells can be assessed alongside viability, caspase activity, mitochondrial status, and membrane-integrity measurements. A G0/G1 phenotype should be confirmed by DNA-content analysis or an equivalent cell-cycle assay. A decrease in cell number alone cannot distinguish cytostasis from apoptosis.

B-cell lymphoma research may also be considered as a model context for BMX signaling, but the supplied dossier does not establish efficacy or selectivity in B-cell lymphoma cells. Such work requires direct testing in authenticated lymphoma models with appropriate Tec-family kinase controls.

Why this cross-domain matters, maturity, and limitations

The oncology-to-infectious-disease bridge is mechanistically plausible because both domains can depend on host kinase signaling. The cited Mtb study provides peer-reviewed evidence that BMX participates in ATP6V1E1 phosphorylation, V-ATPase assembly, lysosomal acidification, and intracellular bacterial survival (Chen et al., 2026). The product dossier provides compound-level evidence for BMX inhibition and cancer-cell phenotypes (product information). The maturity is therefore pathway-level for Mtb biology and reagent-level for BMX studies, not clinical validation. A direct BMX-IN-1 test in infected macrophages, with cytotoxicity and bacterial-load controls, is required before attributing an antimicrobial phenotype to this compound.

Common Pitfalls or Misconceptions

• Misconception: irreversible means universally selective. Covalent binding can be durable, but off-target covalent interactions remain possible. Confirm selectivity in the intended panel or cell system.
• Misconception: a 300 nM response is a universal working concentration. The reported low concentration applies to specified cellular models after 24 hours. It should not be transferred directly to another cell line, exposure time, or endpoint.
• Misconception: G0/G1 arrest proves apoptosis. Arrest and apoptosis are distinct outcomes. Measure both phenotypes independently.
• Misconception: BMX-IN-1 is already validated as an anti-TB drug. The cited study supports BMX as a host-pathogen pathway component, but it does not establish clinical efficacy or safety for BMX-IN-1.
• Misconception: DMSO solubility implies aqueous solubility. The dossier states that the compound is insoluble in water and ethanol. Vehicle controls are essential.

Mtb Inhibits Lysosomal Acidification via BMX-Dependent ATP6V1E1 Phosphorylation emphasizes the host-pathogen mechanism; this article extends it by separating that mechanism from BMX-IN-1-specific product evidence.

BMX Kinase-Driven ATP6V1E1 Phosphorylation in Mtb Survival focuses on BMX-dependent bacterial survival; this article adds formulation, storage, and cellular assay boundaries for the inhibitor.

BMX-IN-1: Selective Irreversible BMX Kinase Inhibitor presents a broad cancer and infectious-disease use case; this article clarifies which claims are directly supported by the cited product dossier and peer-reviewed Mtb study.

Workflow Integration & Parameters

The workflow should begin with a defined biological question. Use biochemical assays to test BMX inhibition and cellular assays to test downstream phenotypes. Use vehicle-only controls, untreated controls, and a comparator strategy appropriate to the question. Because the compound is described as irreversible, record exposure duration and washout conditions.

Protocol Parameters

• Identity: Use BMX-IN-1, CAS 1431525-23-3, or SKU A3260 as the compound identifier; verify lot-specific documentation before starting an assay.
• Stock solvent: Prepare stocks in DMSO because the product information reports DMSO solubility at concentrations of at least 5.25 mg/mL; calculate the final vehicle percentage for every treatment.
• Aqueous handling: Do not assume solubility in water or ethanol because the product information describes the compound as insoluble in both solvents.
• Storage: Store the solid at -20°C according to the product information. Protect prepared solutions from prolonged storage and use them promptly.
• Cell-cycle assay: Evaluate G0/G1 distribution under the exposure duration selected for the model. The dossier reports activity as low as 300 nM after 24 hours, but this is a reference condition rather than a universal dose.
• Apoptosis assay: Pair viability measurements with an apoptosis-specific endpoint and report concentration, exposure time, cell density, and vehicle percentage.
• Mtb pathway study: Treat BMX-IN-1 testing in infected macrophages as a hypothesis-driven extension of the cited BMX–ATP6V1E1 mechanism. Measure lysosomal acidification, ATP6V1E1 phosphorylation, host-cell viability, and bacterial burden in parallel.
• Mechanistic attribution: Use target-engagement or pathway-rescue experiments where feasible. A phenotypic change alone cannot prove that BMX inhibition caused the result.

Conclusion & Outlook

BMX-IN-1 is a selective, irreversible BMX kinase inhibitor with a covalent mechanism and reported cellular effects that include proliferation reduction, G0/G1 arrest, and apoptosis induction. Its stated physical properties support DMSO-based preparation and cold storage of the solid.

The strongest immediate use is controlled investigation of BMX-dependent signaling in cancer and vascular biology. The 2026 Mtb study adds a distinct host-pathogen rationale by connecting BMX to ATP6V1E1 phosphorylation and lysosomal acidification. The next evidence needed for a cross-domain claim is direct testing of BMX-IN-1 in the relevant infection model with matched host-toxicity, pathway, and bacterial-growth measurements. Until those data exist, BMX-IN-1 should be treated as a mechanistic research tool rather than a validated treatment.